Before you sell to, join or invest in Latigo Biotherapeutics, Inc.
MentionFox check on Latigo Biotherapeutics, Inc.: only 1 source on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/latigo-biotherapeutics-inc-form-d-25000001
Check Latigo Biotherapeutics, Inc. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about Latigo Biotherapeutics, Inc.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
Latigo Biotherapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-02-13.
Latigo Biotherapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on February 13, 2025. The filing reports $50M sold. Its industry group is Biotechnology. It names Nima Farzan (Executive Officer, Director), Kevin Raidy (Director), Jim Tananbaum (Director) (SEC Form D, February 13, 2025).
Is this your company?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Sell to companies like Latigo Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Latigo Biotherapeutics, Inc.
Free to see. No signup.
Get an email when Latigo Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Latigo Biotherapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Latigo Biotherapeutics, Inc. →Get the full cited report on Latigo Biotherapeutics, Inc.
What the filing shows about Latigo Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Latigo Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Latigo Biotherapeutics, Inc.'s address as 1300 Rancho Conejo Blvd. Suite 305, Thousand Oaks, CA 91320.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Latigo Biotherapeutics, Inc. See pricing
Latigo Biotherapeutics, Inc. is a registered filer with the SEC (CIK 2056611) and has filed since 2025-02-13. 1 filing is on record, the latest on 2025-02-13.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Latigo Biotherapeutics, Inc.'s Form D of 2025-02-13 names Nima Farzan, Kevin Raidy, Jim Tananbaum and 5 more as its officers, directors or promoters.
Its new offerings report $50M sold across 1 offering, as its own filings state.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
Nima Farzan is named as Executive Officer and Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Kevin Raidy is named as Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Jim Tananbaum is named as Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Beth Seidenberg is named as Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Deborah Palestrant is named as Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Tim Walbert is named as Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Nancy Stagliano is named as Director on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
Tim Lugo is named as Executive Officer on the Form D that Latigo Biotherapeutics, Inc. filed with the SEC on 13 February 2025, one of 8 people that filing names.
8 people named on the filing — 2 holding an executive role and 6 as directors only.
Named as of the 2025-02-13 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Latigo Biotherapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Latigo Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Latigo Biotherapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Latigo Biotherapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Latigo Biotherapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Latigo Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Los Angeles
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/latigo-biotherapeutics-inc-form-d-25000001